Compare AMPY & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AMPY | MDXH |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.6M | 183.4M |
| IPO Year | 2011 | 2021 |
| Metric | AMPY | MDXH |
|---|---|---|
| Price | $5.17 | $3.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 570.0K | 123.5K |
| Earning Date | 03-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $275,827,100.00 | $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $2.27 | $1.35 |
| 52 Week High | $6.55 | $5.33 |
| Indicator | AMPY | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 48.33 |
| Support Level | $5.18 | $3.45 |
| Resistance Level | $5.75 | $3.80 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 47.12 | 27.50 |
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.